Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04989803 · ClinicalTrials.gov registry record · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
A Phase 1 study of Relapsed and/or Refractory B-cell Lymphoma, sponsored by Kite, A Gilead Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 247
- Enrollment target
- 14
- Study locations
NCT04989803: Recruiting Phase 1 study of Relapsed and/or Refractory B-cell Lymphoma, sponsored by Kite, A Gilead Company.
NCT04989803 is a Phase 1 study of Relapsed and/or Refractory B-cell Lymphoma that is actively recruiting participants, run by Kite, A Gilead Company. The registered enrollment target is 247 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (312% higher). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04989803, a Phase 1 study of Relapsed and/or Refractory B-cell Lymphoma, is actively recruiting participants, sponsored by Kite, A Gilead Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 247 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Primary Outcome
DLTs are defined as the KITE-363-related or KITE-753-related events with onset within the first 28 days after the infusion of KITE-363 or KITE-753 respectively.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL KITE-363
- BIOLOGICAL KITE-753
Study Locations (14)
Other
- Universitatsklinikum Wurzburg - Würzburg
- Academisch Medisch Centrum - Amsterdam
- King's College Hospital - London
New York
- Columbia University Irving Medical Center - New York
- University of Rochester Medical Center - Rochester
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- Stanford Cancer Institute - Stanford
Georgia
- Northside Hospital - Atlanta
Maryland
- University of MD, Greenebaum Comprehensive Cancer Center - Baltimore
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- The Ohio State University Wexner Medical Center - James Cancer Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT04989803 shows while recruiting
NCT04989803 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (312% higher).
The record links to 1 condition, with Relapsed and/or Refractory B-cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04989803 lists 14 locations in 11 states (Other, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT04989803 about?
NCT04989803 is a clinical study titled "Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma". The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
What is the current status of trial NCT04989803?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 247 participants. The study started on 2021-10-27. Estimated completion is 2027-10.
What conditions does trial NCT04989803 study?
This clinical trial studies the following conditions: Relapsed and/or Refractory B-cell Lymphoma.
What interventions are being tested in trial NCT04989803?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-363 (BIOLOGICAL), KITE-753 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04989803?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04989803 being conducted?
This trial has 14 study locations across Arizona, California, Georgia, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04989803's enrollment target sits among peer trials
247 188th of 2000 higher than 1,813 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI